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Background: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be 
constitutively activated through genomic amplification or activating point mutations. 
We studied ALK genetic alterations in high-risk NB patients to determine their 
frequency and prognostic impact. 
 
Methods: Diagnostic NB samples from 1039 patients enrolled in the SIOPEN-HR-
NBL1 trial were studied to determine the ALK amplification status (copy number 
analysis; n=337), the ALK mutational profile (Sanger and/or NGS including deep 
sequencing, n=203) or both (n=499). 
The sensitivity of ALK mutated/ALK amplified or ALK wildtype NB cell lines ((CLB-GA 
(R1275Q), CLB-GE (F1174V; ALK-A), SKNBE-2C (ALK wt)) to simultaneous or 
consecutive combinations of ALK TKIs (crizotinib/lorlatinib) and/or chemotherapy 
(Etoposide and Doxorubicin) was then tested.  
 
Results: Genomic ALK amplifications were detected in 4.4% of cases (37/836); all 
but 2 showed MYCN amplification. ALK mutations were detected at a clonal level 
(>20% mutated allele fraction, MAF) in 9.8% of cases (69/702) (F1174 n=25, R1275 
n=32, both F1174 and R1275 n=1, F1245 n=6, others n=5) and at a subclonal level 
(MAF 0.5-20%) in 3.7% of patients (22/586) (F1174 n=11, R1275 n=6, both F1174 
and R1275 or F1174 and F1245 n=3, other n=2).  
 
A significantly poorer OS and EFS was observed in cases with clonal ALK mutations, 
versus all others (3-years OS 47% +/-6.4% versus 65% +/-2%, logrank, p< 0.0001) 
and in those with ALK amplifications, versus all others (3-years OS 31% +/-8.5% 
versus 66% +/- 1.9%; logrank, p<0.0001).  
 
A Cox proportional hazards procedure (450 patients with complete clinical/biological 
datasets) retained stage 4 disease (as opposed to non-stage 4) and ALK 
amplification as factors with a higher hazard of relapse/progression (hazard 2.3 and 
2.2, respectively), whereas ALK mutation, MYCN amplification and age>18 months 
were not retained. 
 
The consecutive treatment of Doxorubicin followed by Lorlatinib had a synergistic 
effect in ALK mutated/amplified NB cell lines. 
 
Conclusion: Genetic alterations of ALK (clonal mutations, amplifications) in high-risk 
NB patients are associated with poorer survival. Further preclinical data are required 
to determine optimal treatment modalities for integration of TKI in upfront treatment 
strategies of HR NB patients with ALK alterations. 
 
 
